相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Berberine (BBR) Attenuated Palmitic Acid (PA)-Induced Lipotoxicity in Human HK-2 Cells by Promoting Peroxisome Proliferator-Activated Receptor α (PPAR-α)
Yueyue Wu et al.
MEDICAL SCIENCE MONITOR (2019)
Management of Statin Intolerance in 2018: Still More Questions Than Answers
Peter P. Toth et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials
Ju Jianqing et al.
PHYTOMEDICINE (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Arrigo F. G. Cicero et al.
ARCHIVES OF MEDICAL SCIENCE (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Alan Chait et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Current knowledge and pharmacological profile of berberine: An update
Anil Kumar et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
An assessment by the Statin Muscle Safety Task Force: 2014 update
Robert S. Rosenson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
An assessment by the Statin Cognitive Safety Task Force: 2014 update
Carlos H. Rojas-Fernandez et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Kevin C. Maki et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
An-Wen Chan et al.
ANNALS OF INTERNAL MEDICINE (2013)
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Giuseppe Derosa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
An-Wen Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
Flora Affuso et al.
WORLD JOURNAL OF CARDIOLOGY (2012)
Combination of simvastatin with berberine improves the lipid-lowering efficacy
Wei-Jia Kong et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway
F. L. Chen et al.
ENDOCRINE (2008)
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states
Yun S. Lee et al.
DIABETES (2006)
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
WJ Kong et al.
NATURE MEDICINE (2004)
分享论文
